Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Girijavallabhan
Reshma Girijavallabhan, Denville, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20100152646 | Intravitreal injection device and method - A coordinated cutting and spreading mechanism within a syringe dilator sub-assembly is applied to an eye surface during an intravitreal injection to provide an access window free of the conjunctival layer and through which an injection needle can be inserted. The system and method comprises a dilator sub-assembly including both the cutting and spreading mechanism and the intravitreal injection needle, for use with a conventional syringe. The dilator sub-assembly includes a number of projections to secure points of the surface of the conjunctival layer, a cutting member to incise the conjunctival layer, and at least one deflectable projection to move during the intravitreal injection, spreading the incision, and creating a window opening in the conjunctival layer through which the intravitreal injection needle then enters. Upon removal of the device from the injection site, the deflectable projection is released and the window opening in the conjunctival layer is closed. | 06-17-2010 |
Vinay Girijavallabhan, Denville, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20120010181 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof. | 01-12-2012 |
Vinay M. Girijavallabhan, Denville, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090156586 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 06-18-2009 |
| 20100120838 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 05-13-2010 |
| 20100145048 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 06-10-2010 |
| 20110318305 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS - The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R | 12-29-2011 |
Vinay M. Girijavallabhan, Watertown, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090137586 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 05-28-2009 |
| 20090170875 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 07-02-2009 |
Viyyoor M. Girijavallabhan, Parsippany, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110150835 | Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease - The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. | 06-23-2011 |
Viyyoor Moopil Girijavallabhan, Parsippany, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110117057 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS - The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. | 05-19-2011 |